Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure

Journal of Cardiology

Volumn 39, Issue 3, 2002, Pages 159-164

  Shiga, Tsuyoshi ^a   Matsuda, Naoki ^a   Fuda, Yuji ^a   Haruta, Shoji ^a   Hagiwara, Nobuhisa ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic agents (nifekalant); Atrial fibrillation; Atrial flutter; Heart failure; QT interval

Indexed keywords

ANTIARRHYTHMIC AGENT; NIFEKALANT; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; INOTROPISM; MALE; QT INTERVAL; QT PROLONGATION; SUPRAVENTRICULAR TACHYCARDIA; CONGESTIVE HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TACHYCARDIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRIMIDINONES; TACHYCARDIA;

EID: 0036515279     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Crijns HJGM, Van den Berg MP, Van Gelder IC, Van Veldhuisen DJ: Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18 (Suppl C): C45-C49
2. Singh BN: Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 1999; 10: 283-301
3. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC Jr, Meissner MD, Zoble RG, Wakefield RK, Perry KT, Vanderlugt JT, for the Ibutilide Investigators: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996; 28: 130-136
4. Falk RH, Pollak A, Singh SN, Friedrich T, for the Intravenous Dofetilide Investigators: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997; 29: 385-390
5. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gangé P, Nattel S, Thibault B, for the Canadian Trial of Atrial Fibrillation Investigators: Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-920
6. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbæk J, Marchant B, Camm AJ, for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-865
7. Pritchett ELC, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE, and the Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators: Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. J Am Coll Cardiol 2000; 36: 794-802
8. Nakaya H, Uemura H: Electropharmacology of nifekalant, a new class III antiarrhythmic drug. Cardiovas Drug Rev 1998; 16: 133-144
9. Isomoto S, Konoe A, Centurion OA, Hayano M, Kaibara M, Hirata T, Yano K: Electrophysiological effects of MS-551 in humans: A class III antiarrhythmic agent. Pacing Clin Electrophysiol 1995; 18: 2022-2027
10. Kato T, Tsunoo M, Mitsuhashi T, Atarashi H, Ino T, Kuroki S, Tanaka T, Kamei S, Endo Y, Nomura A, Hayakawa K, Hirata H: Phase I study of MS-551 (1): A single intravenous injection study. J Clin Ther Med 1997; 13: 1659-1674 (in Jpn with Eng abstr)
11. Rensma PL, Allessie MA, Lammers WJEP, Bonke FIM, Schalij MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410
12. Gaspo R, Bosch RF, Talajic M, Nattel S: Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997; 96: 4027-4035
13. Kumagai K, Gondo N, Matsuo K, Annoura M, Muroe K, Nakashima Y, Hiroki T, Arakawa K: Wavelength index: A predictor of the response to disopyramide in paroxysmal lone atrial fibrillation. Cardiology 1994; 85: 184-192
14. Ishii M, Kamiya J, Hashimoto K: Cellular electrophysiological effects of MS-551, a novel class III anti-arrhythmic agent. Drug Dev Res 1995; 35: 61-68
15. Kunimoto S, Watanabe I, Kojima T, Kanda A, Kondo K, Takahashi Y, Kajita J, Saito S, Ozawa Y, Kanmatsuse K: Electrophysiological effect of a novel class III anti arrhythmic agent, MS-551 on human atrium and ventricle. Jpn J Cardiac Pacing Electrophysiol 1995; 11: 257-282 (in Jpn with Eng abstr)
16. Watanabe H, Watanabe I, Nakai T, Oshikawa N, Kunimoto S, Masaki R, Kojima T, Saito S, Ozawa Y, Kanmatsuse K: Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,1-sotalol on the human atrium. Jpn Circ J 2001; 65: 1-6
17. Hayashi H, Fujiki A, Tani M, Usui M, Inoue H: Different effects class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart. J Cardiovasc Pharmacol 1998; 31: 101-107
18. Shinagawa K, Mitamura H, Sato T, Kanki H, Takatsuki S, Ogawa S: Effect of Na and K channel blockers on the spatial and temporal dispersion of atrial refractoriness during atrial fibrillation. Jpn J Electrocardiol 1998; 18: 433-442 (in Japanese)
19. Kanki H, Mitamura H, Takatsuki S, Sueyoshi K, Shinagawa K, Sato T, Ogawa S: Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther 1998; 12: 475-482
20. Kato K, Inoue H, Iinuma H, Ohe T, Ogawa S, Kasanuki H, Kato T: Efficacy of intravenous doses of MS-551 for paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation or flutter: Phase II study. J Clin Ther Med 1997; 13: 1745-1758 (in Jpn with Eng abstr)
21. Li D, Benardeau A, Nattel S: Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000; 102: 104-112
22. Ravelli F, Allessie M: Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997; 96: 1686-1695
23. Shiga T, Ando S, Suzuki T, Matsuda N, Kasanuki H: Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction. J Electrocardiol 2001; 34: 77-80